Even before Europe's new clinical trials directive (2001/20/EC) was signed into EU law, some research bodies were warning that it would have a devastating impact on academic clinical trials. Now, with just 2 months to go until the law is supposed to be enacted by member countries on May 1, groups like the European Organization for Research and Treatment of Cancer (EORTC) are still lobbying hard in the hope that something can be done to avoid what they see as a disaster in the making.

The aim of the directive is to make the regulation of clinical trials across the European Union uniform while protecting participants. The problems, as some researchers see them, lie in increased legal and financial burdens that the law imposes on the organizers of a trial.

These include strict reporting and monitoring rules, drug manufacturing for marketed drugs, fees to ethics committees and authorities, and increased...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?